Raloxifene is a second generation selective estrogen receptor modulator (SERM) with FDA approval for both osteoporosis prevention and treatment and breast cancer risk reduction. A dual regulatory approval history that contributes one of the most extensive human clinical literature bases of any SERM in current research, second only to Tamoxifen in documented clinical investigation depth. This formulation delivers 60mg per tablet in a 30 count format, consistent with the concentration most commonly referenced in osteoporosis and breast cancer risk reduction clinical research literature.

Raloxifene’s tissue selective estrogen receptor profile distinguishes it meaningfully from both Tamoxifen and Clomiphene within CSD’s SERM range. Like all SERMs, Raloxifene acts as an estrogen antagonist in some tissues and a partial agonist in others but its specific tissue selectivity pattern differs from Tamoxifen’s in research relevant ways. Raloxifene acts as an estrogen antagonist in breast tissue and the uterus; unlike Tamoxifen which carries partial agonist activity at the uterine endometrium. While exerting estrogen agonist effects on bone metabolism and lipid profiles. This uterine antagonism distinguishes Raloxifene’s safety profile from Tamoxifen in endometrial tissue research and has generated specific comparative SERM research into tissue selectivity differences between second and first generation SERM compounds.

Raloxifene’s HPG axis activity profile is also distinct from Clomiphene and Tamoxifen. While it does exert hypothalamic and pituitary estrogen receptor modulation, its primary clinical research applications have centered on bone metabolism, cardiovascular lipid effects, and breast tissue estrogen receptor antagonism rather than gonadotropin stimulation. This different primary research focus makes Raloxifene a complementary rather than interchangeable research tool from CSD’s other SERMs, valuable in studies examining SERM tissue selectivity comparisons, bone metabolism estrogen receptor activity, and the structural basis of differential tissue responses across the SERM compound class.

Every batch of CSD’s Raloxifene is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our SERM range: Tamoxifen, Clomiphene, Enclomiphene, and Raloxifene. It covers first and second generation selective estrogen receptor modulator research from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store in a cool, dry place away from direct light and heat. Intended for research purposes only.

Commonly researched alongside Tamoxifen in comparative SERM tissue selectivity and estrogen receptor modulation studies. Browse CSD’s full PCT and hormone research range for complete sourcing.